Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified

Abstract Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatment is not effective. In this paper, we reported 6 R/R patients diagnosed as ALAL-NO...

Full description

Bibliographic Details
Main Authors: Kaiqi Liu, Yan Li, Shaowei Qiu, Chunlin Zhou, Shuning Wei, Dong Lin, Guangji Zhang, Hui Wei, Ying Wang, Bingcheng Liu, Xiaoyuan Gong, Qiuyun Fang, Yang Song, Huijun Wang, Chengwen Li, Qinghua Li, Lihua Wu, Benfa Gong, Yuntao Liu, Jianxiang Wang, Yingchang Mi
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Experimental Hematology & Oncology
Subjects:
Efficacy
venetoclax
ALAL-NOS
Relapse
Refractory
Online Access:https://doi.org/10.1186/s40164-021-00239-w

Internet

https://doi.org/10.1186/s40164-021-00239-w

Similar Items